Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Shanghai Chest Hospital
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05988697CT.gov Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib | — | Not Yet Recruiting | — | — | — |
NCT06018688CT.gov Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients. | — | Not Yet Recruiting | — | — | — |
NCT03532698CT.gov Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC) | — | Unknown | — | — | — |
NCT04184921CT.gov Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients | — | Completed | — | — | — |
NCT03236935CT.gov Phase Ib of L-NMMA and Pembrolizumab | — | Completed | — | — | — |
NCT03543683CT.gov Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC | — | Completed | — | — | — |
NCT02387086CT.gov Gefitinib Combined With Thalidomide to Treat NSCLC | — | Unknown | — | — | — |
NCT01707823CT.gov Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Aspirin (this asset) | Shanghai Chest Hospital | P3 | B · 62 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Aspirin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myocardial Infarction | — | P4 | A · 83 |
| Coronary Artery Disorder | — | P4 | BBB · 79 |
| Cardiovascular Disorder | — | P4 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Aspirin in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/aspirin-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →